Claims
- 1. A method of treating bacterial infections in mammals by administering to a mammal suffering from such infection a therapeutically effective amount of a compound selected from those of the formula 1: ##STR20## wherein R is hydrogen,C.sub.1 to C.sub.6 lower alkyl or aryl-C.sub.1 to C.sub.6 alkyl;
- Z.sup.1, Z.sup.2, and Z.sup.3 are independently H, halogen, C1-C6 alkyl, C1-C6 alkoxy, hydroxy, amino, or nitro;
- m is an integer from 1-5;
- X is CH.sub.2 O, CH.sub.2 S, CH.sub.2 NR, C(O)NR, CH.sub.2 OC(O)CH.sub.2, or CH.sub.2 OC(O)CH.sub.2 CH.sub.2 ;
- Ar is aryl optionally substituted with one to three substituents, selected from halogen, hydroxy, C1-C6 alkyl and C1-C6 alkoxy;
- W is oxygen, sulfur, or a bond;
- n is an integer from 0-5;
- A is selected from moieties of the formulae: ##STR21## aryl is phenyl, biphenyl or naphthyl; with the proviso that;
- where n is 0 or 1, W is a bond;
- and the pharmaceutically acceptable salts and prodrug forms thereof.
- 2. A method according to claim 1 wherein X is selected from CH.sub.2 O and CH.sub.2 S.
- 3. A method according to claim 1 wherein Ar is selected from 1,2-phenylene, 1,3-phenylene, 1,4-phenylene, 1,6-naphthylene, 6,1-naphthylene, 1,5-naphthylene, 2,5-naphthylene, 5,2-naphthylene, and 2,6-naphthylene.
- 4. A method according to claim 1 wherein:
- X is selected from CH.sub.2 O, and CH.sub.2 S;
- Ar is selected from 1,2-phenylene, 1,3-phenylene, 1,4-phenylene, 1,6-naphthylene, 6,1-naphthylene, 1,5-naphthylene, 2,5-naphthylene, 5,2-naphthylene, and 2,6-naphthylene;
- where Ar may optionally be further substituted with one to three substituents selected from halogen, C1-C6 alkyl, hydroxy, and C1-C6 alkoxy;
- n is 0, 1, 2, or 3;
- m is 1;
- W is a bond;
- A is selected from piperidine and tetra-hydropyridine; and
- aryl is phenyl, biphenyl or naphthyl;
- and the pharmaceutically acceptable salts and prodrug forms thereof.
- 5. A compound selected from those of the formula 1: ##STR22## wherein R is hydrogen,C.sub.1, to C.sub.6 lower alkyl or aryl-C.sub.1, to C.sub.6 alkyl;
- Z.sup.1, Z.sup.2, and Z.sup.3 are independently H, halogen, C1-C6 alkyl, C1-C6 alkoxy, hydroxy, amino, or nitro;
- m is an integer from 1-5;
- X is CH.sub.2 O, CH.sub.2 S, CH.sub.2 NR, C(O)NR, CH.sub.2 OC(O)CH.sub.2, or CH.sub.2 OC(O)CH.sub.2 CH.sub.2 ;
- Ar is aryl optionally substituted with one to three substituents selected from halogen, hydroxy, C.sub.1 -C6 alkyl and C .sub.1 -C6 alkoxy;
- W is oxygen, sulfur, or a bond;
- n is an integer from 0-5;
- A is selected from moieties of the formulae: ##STR23## aryl is phenyl, biphenyl or naphthyl; with the proviso that;
- where n is 0 or 1, W is a bond;
- and the pharmaceutically acceptable salts and prodrug forms thereof.
- 6. A compound according to claim 5 wherein X is selected from CH.sub.2 O and CH.sub.2 S.
- 7. A compound according to claim 5 wherein Ar is selected from 1,2-phenylene, 1,3-phenylene, 1,4-phenylene, 1,6-naphthylene, 6,1-naphthylene, 1,5-naphthylene, 2,5-naphthylene, 5,2-naphthylene, and 2,6-naphthylene.
- 8. A compound according to claim 5 wherein:
- X is selected from CH.sub.2 O, and CH.sub.2 S;
- Ar is selected from 1,2-phenylene, 1,3-phenylene, 1,4-phenylene, 1,6-naphthylene, 6,1-naphthylene, 1,5-naphthylene, 2,5-naphthylene, 5,2-naphthylene, and 2,6-naphthylene;
- where Ar may optionally be further substituted with one to three substituents selected from halogen, C.sub.1 -C6 alkyl, hydroxy, and C 1-C6 alkoxy;
- n is 0, 1, 2, or 3;
- m is 1;
- W is a bond;
- A is selected from piperidine and tetra-hydropyridine; and
- aryl is phenyl, biphenyl or naphthyl;
- and the pharmaceutically acceptable salts and prodrug forms thereof.
- 9. A pharmaceutical composition for treating bacterial infections comprising an effective amount of a compound selected from claim 5 in association with a pharmaceutically acceptable carrier.
Parent Case Info
This is a Continuation-in-Part, of application Ser. No. 08/459,446, filed Jun. 2, 1995, now U.S. Pat. No. 5,643,950.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
5643950 |
Demers et al. |
Jul 1997 |
|
Non-Patent Literature Citations (3)
Entry |
M. J. Mahan, J. M. Slauch and J. J. Mekalanos, Science, 259, 686-688 (1993). |
S. Roychoudhury et al., Proc. Nat. Acad. Sci., 90, 965-969 (1993). |
Inhibitors of Two-Component Signal Transduction Systems: Inhibition of Alginate Gene Activation in Pseudomonas Aeruginosa. |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
459446 |
Jun 1995 |
|